Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 8Recruiting 6Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Genitourinary 1CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 19daratumumab 16Lenalidomide 11Bortezomib 9Cyclophosphamide 8pomalidomide 7Calcium Dobesilate 6fludarabine 4carfilzomib 4belantamab mafodotin 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Melphalan 3Biopsy 3tocilizumab 2isatuximab 2Stem Cell Transplantation 2Sirolimus 2Maintenance 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × X-Rays × Plasma cell × Clear all
NCT04579523 2026-03-13

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡